Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at Hard-to-Treat lung cancer

NCT ID NCT06348797

Recruiting now ⭐️ CURE ⭐️ Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 1 trial tests a new type of CAR-T cell therapy designed to target a protein called DLL3 found on small cell lung cancer cells. The CAR-T cells are also modified to boost their activity through PD-L1 and 4-1BB signals. The study enrolls adults with relapsed or refractory extensive-stage small cell lung cancer who have already tried one platinum-based chemotherapy. Participants receive low-dose chemotherapy and some may get targeted radiotherapy before the CAR-T infusion, with the goal of finding a safe dose and seeing if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a modified CAR-T cell therapy targeting DLL3, combined with PD-L1/4-1BB signaling enhancement, given after low-dose chemotherapy and optional radiotherapy
What this could lead to
If successful, this could point toward a durable treatment option for relapsed small cell lung cancer, a disease with few effective therapies.
What could go wrong
This is an early phase 1 trial with only 30 participants, so safety and dosing are still being established. CAR-T therapy can cause severe side effects like cytokine release syndrome, and it may not shrink tumors in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER EXTENSIVE STAGE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.